Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb STAT Nawigacja wpisu BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline – Fierce Biotech Prime Medicine Unveils Strategically Focused Pipeline – GlobeNewswire
